From Yahoo Finance: 2025-05-31 08:46:00

JonesResearch upgraded BioLineRx (BLRX) to Buy with a $12 price target. New pilot phase data from a Phase II trial showed 7 of 11 patients responded to therapy, with 10 of 11 achieving disease control. Analysts believe BioLineRx has potential for future partnerships or funding for a pivotal trial based on these positive results.

The ultimate source for real-time, market-moving financial news, TheFly, published this update on BioLineRx. For more information on top-performing stocks, visit TipRanks for today’s best picks.

For more information on BioLineRx, including disclaimer and disclosure details, visit TipRanks. Stay informed on the latest news and developments in the stock market.

Read more: BioLineRx upgraded to Buy from Hold at JonesResearch